All In Biotech

Drug Trial Radar · NCT06659263

RE104 Clinical Lactation Study

A Phase 1, Open-label, Single Dose Study to Evaluate the Concentration of RE104 and Its Major Metabolites in Breast Milk and Plasma of Healthy Lactating Women.

Last checked: Nov 19, 2026Latest source record: Jun 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Nov 13, 2024

Primary completion

May 28, 2025

Study completion Jun 4, 2025

Sponsor

Lead sponsor
Reunion Neuroscience IncIndustry
Sponsor type
Industry
First posted
Oct 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to obtain data necessary to characterize the elimination of RE104 and metabolites from breastmilk of health lactating volunteers to support a regulatory assessment of when mothers can safely return to breastfeeding following a single-dose of RE104 for Injection.

Conditions

  • Lactation

Interventions

  • RE104 for InjectionDrug

    Single, subcutaneous dose of RE104 for Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time curve from time zero to 24 hours post-dose (AUC0 24) for RE104 and 4-OH-DiPT in plasma and breast milkTime frame: Through 24 hours postdose
  2. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for RE104 and 4-OH-DiPT in plasma and breast milkTime frame: Through 168 hours postdose
  3. Maximum observed concentration (Cmax) for RE104 and 4-OH-DiPT in plasma and breast milkTime frame: Through 168 hours postdose
  4. Time to reach Cmax (tmax) for RE104 and 4-OH-DiPT in plasma and breast milkTime frame: Through 168 hours postdose
  5. Apparent total body clearance (CL/F) for RE104 in plasmaTime frame: Through 168 hours postdose
  6. Apparent volume of distribution during the terminal phase (Vz/F) for RE104 in plasmaTime frame: Through 168 hours postdose
  7. Apparent terminal elimination half-life (t1/2) for RE104 and 4-OH-DiPT in plasmaTime frame: Through 168 hours postdose
  8. Milk to plasma (M/P) ratio for RE104 and 4-OH-DiPT in breast milkTime frame: Through 168 hours postdose
  9. Relative infant dose (RID) of RE104 and its active entity 4-OH-DiPTTime frame: Through 72 hours postdose
  10. Total RID of RE104 and its active entity 4-OH-DiPTTime frame: Through 168 hours postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD Inc

    Las Vegas, Nevada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.